Navigation Links
New Drug Boosts 'Good' Cholesterol in Study Patients
Date:9/13/2011

TUESDAY, Sept. 13 (HealthDay News) -- A treatment currently being studied may prevent progression of atherosclerosis, a condition caused by the build-up of plaque in artery walls that can lead to heart attack, according to new research.

In conducting the study, published in the Sept. 12 issue of The Lancet, researchers followed 130 patients with atherosclerosis who were randomly assigned to be treated with either the experimental heart drug dalcetrapib, or an inactive placebo over the course of two years. In the double-blind study, neither the researchers nor the patients knew who was taking the heart drug and who was taking the placebo.

While statin drugs are commonly used to lower LDL or "bad" cholesterol to reduce the risk of coronary artery disease, dalcetrapib raises HDL or "good" cholesterol in order to reduce the risk, the researchers explained.

To determine the efficacy of dalcetrapib, the researchers used non-invasive imaging technology. Through MRI, the researchers found the patients on dalcetrapib had a 31 percent increase in "good" HDL cholesterol levels. Additional PET/CT scans showed that inflammation levels in the carotid artery of patients were significantly reduced only among those taking dalcetrapib. The carotid arteries are responsible for supplying oxygenated blood to the head and neck.

In a different study, a drug in the same class designed to raise HDL levels was tied to an increase in death linked to vascular inflammation, but the researchers did not find an increase in such inflammation with dalcetrapib.

"This milestone study shows that MRI and PET/CT are highly useful in assessing the safety and efficacy of dalcetrapib, and that this novel therapy may address a significantly unmet need in cardiovascular disease," said lead study author Zahi A. Fayad, a professor of radiology and medicine in the cardiology division at Mount Sinai School of Medicine and the director of its Translational and Molecular Imaging Institute, in a Mt. Sinai news release.

"We are excited about the results obtained in this trial, which could have a great impact on the treatment of patients with cardiovascular disease," said Fayad, who disclosed receiving financial compensation as a scientific advisory board member from the study's sponsor, Hoffmann-La Roche, whose holding company makes dalcetrapib.

Fayad noted imaging technology could be a vital tool for evaluating other treatments for heart disease.

More information

The U.S. National Library of Medicine has more about atherosclerosis.

-- Mary Elizabeth Dallas

SOURCE: Mount Sinai Hospital, news release, Sept. 12, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. TNF Treatment for Rheumatoid Arthritis Boosts Skin Cancer Risk
2. Regular Exercise Boosts the Brain, Too
3. Yoga boosts stress-busting hormone, reduces pain: York U study
4. Stopping Daily Aspirin Boosts Heart Attack Risk: Study
5. Study: Potassium Boosts Heart Health, Salt Harms It
6. Even One Glass of Beer, Wine Boosts Car Crash Risk: Study
7. Mystery ingredient in coffee boosts protection against Alzheimers disease
8. On-the-Job Activity Boosts Americans Exercise Levels
9. Weight Loss in Heavy, Obese Women Boosts Vitamin D Levels
10. Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women
11. Tai Chi Prevents Falls, Boosts Mental Health in Seniors: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Boosts 'Good' Cholesterol in Study Patients
(Date:12/5/2016)... ... December 05, 2016 , ... ... partnership with leading global lifestyle design firm kathy ireland® Worldwide for five additional ... ireland® Worldwide entered into an exclusive licensing agreement three years ago to design ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... geographic lines. The goal of Castlewood Treatment Centers has always been to promote ... to as many people as possible. In that spirit, Castlewood has announced two ...
(Date:12/5/2016)... ... December 05, 2016 , ... Florida Hospital has named Robin ... Region. McGuinness brings experience in executive leadership and clinical practice, as well as ... In her new role, that officially begins December 12, 2016, she will set ...
(Date:12/5/2016)... ... ... MBA has joined the Retina Group of New York (RGONY) specializing in uveitis ... MD and has been providing tertiary medical and surgical retinal care on Long Island for ... her peers. Growing up in a family of doctors, Dr. Shah emulated the role ...
(Date:12/5/2016)... ... December 05, 2016 , ... Z-Medica, ... have teamed up with The American College of Surgeons (ACS) to provide basic ... Trauma, the “Bleeding Control Basic” course is a pilot program that fulfills the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016  John Seng, founder of ... will succeed him as Chief Executive Officer following two consecutive years ... Wilson joined Spectrum as president in 2014 and assumed management of ... received public relations industry recognition as Healthcare Agency of the Year ... ...
(Date:12/5/2016)... Research and Markets has announced the addition of the "Spinal ... to their offering. ... The global spinal implants and surgical devices ... of 5.3% from 2016 to 2021. Factors such as the presence of ... on healthcare, and rising income levels are propelling the growth of the ...
(Date:12/5/2016)... SAN ANTONIO , Dec. 5, 2016  Seno ... opto-acoustic technology as a new tool to improve the ... will present data from its European MAESTRO post-market surveillance ... Antonio Breast Cancer Symposium (SABCS) taking place from ... Center in San Antonio, Texas . ...
Breaking Medicine Technology: